Nirogy Therapeutics Overview
- Year Founded
-
2013
- Status
-
Out of Business
- Employees
-
7
- Latest Deal Type
-
Out of Business
Nirogy Therapeutics General Information
Description
Operator of a transporter target platform intended for chronic diseases such as cancer, autoimmunity, and inflammation. The company's platform utilizes transporter biology, structural biology, and computational chemistry to dissect underlying mechanisms, guide drug design, and development, and inform patient selection strategies for the development of novel medicines, enabling healthcare providers to address today's unmet medical needs.
Contact Information
Website
www.nirogytx.comCorporate Office
- 175 Crossing Boulevard
- Suite 520
- Framingham, MA 01702
- United States
Corporate Office
- 175 Crossing Boulevard
- Suite 520
- Framingham, MA 01702
- United States
Nirogy Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 31-Dec-2024 | Completed | Out of Business | |||
| 4. Later Stage VC (Series A) | 26-Jan-2021 | Completed | Generating Revenue | |||
| 3. Grant | 18-Sep-2020 | Completed | Startup | |||
| 2. Grant | 31-Aug-2020 | $1.94M | Completed | Startup | ||
| 1. Accelerator/Incubator | 01-Jan-2014 | Completed | Startup |
Nirogy Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Nirogy Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nirogy Therapeutics Patents
Nirogy Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022159367-A1 | Inhibitors of monocarboxylate transporters for cancer immunotherapy | Inactive | 19-Jan-2021 | ||
| AU-2020356491-A1 | Bicyclic carboxylates as modulators of transporters and uses thereof | Inactive | 25-Sep-2019 | ||
| CA-3149987-A1 | Bicyclic carboxylates as modulators of transporters and uses thereof | Pending | 25-Sep-2019 | ||
| EP-4034112-A1 | Bicyclic carboxylates as modulators of transporters and uses thereof | Inactive | 25-Sep-2019 | ||
| EP-4034112-A4 | Bicyclic carboxylates as modulators of transporters and uses thereof | Inactive | 25-Sep-2019 | C07D495/04 |
Nirogy Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nirogy Therapeutics FAQs
-
When was Nirogy Therapeutics founded?
Nirogy Therapeutics was founded in 2013.
-
Where is Nirogy Therapeutics headquartered?
Nirogy Therapeutics is headquartered in Framingham, MA.
-
What is the size of Nirogy Therapeutics?
Nirogy Therapeutics has 7 total employees.
-
What industry is Nirogy Therapeutics in?
Nirogy Therapeutics’s primary industry is Drug Discovery.
-
Is Nirogy Therapeutics a private or public company?
Nirogy Therapeutics is a Private company.
-
What is Nirogy Therapeutics’s current revenue?
The current revenue for Nirogy Therapeutics is .
-
How much funding has Nirogy Therapeutics raised over time?
Nirogy Therapeutics has raised $16.5M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
